April 1, 2008
Takeda Pharmaceutical Company Limited
Osaka, Japan, April 1, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced the launch of Takeda Bio Development Center Limited (“Takeda Bio”).
Takeda Bio, which used to be a wholly owned subsidiary of Amgen Inc. (Thousand Oaks, Calif.) in Japan being engaged in the clinical development of the investigational compounds created by Amgen Inc., has become a wholly owned subsidiary of Takeda effective today in accordance with the agreement for transfer of shares between Takeda and Amgen Inc. signed in February 2008.
Takeda Bio will conduct clinical development activities of products, which Takeda licensed from Amgen based on the license agreement signed also in February 2008, across a range of therapeutic areas, including oncology, inflammation, and pain.
“Our company is committed to bringing the innovative potential medicines to the patients with illness and physicians who treat them, through dedicating all the possible efforts into conducting clinical development of the products licensed from Amgen Inc. to Takeda, across a range of therapeutic areas, including oncology, inflammation, and pain.” said Hiroyasu Nakamura, president of Takeda Bio.
“We expect that the launch of Takeda Bio is a key step toward enhancement of our franchises in Japan such as cancer and bone/joint diseases among our core therapeutic areas,” said Yasuchika Hasegawa, president of Takeda. “We believe that, as a member of Takeda group, Takeda Bio will contribute to achievement of our Mission, “striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products”.
# # #